UGT1A1*28 POLYMORPHISM AND THE RISK OF TOXICITY AND DISEASE PROGRESSION IN PATIENTS WITH BREAST CANCER RECEIVING SACITUZUMAB GOVITECAN.
Novembre 18, 2024/da LuisaCHARACTERISTICS AND CLINICAL OUTCOMES OF BREAST CANCER IN YOUNG BRCA CARRIERS ACCORDING TO TUMOR HISTOLOGY
Novembre 10, 2024/da Luisa15 GENNAIO 2024, VERONA AIGOM-GIST AVANZATI: IL VALORE DELLA GESTIONE MULTIDISCIPLINARE DEL PAZIENTE
Novembre 9, 2024/da LuisaNEOADJUVANT CHEMOTHERAPY WITH OXALIPLATIN AND FLUOROPYRIMIDINE VERSUS UPFRONT SURGERY FOR LOCALLY ADVANCED COLON CANCER: THE RANDOMIZED, PHASE III OPTICAL TRIAL.
Novembre 5, 2024/da LuisaNEOADJUVANT DOCETAXEL, OXALIPLATIN, AND S-1 PLUS SURGERY AND ADJUVANT S-1 FOR RESECTABLE ADVANCED GASTRIC CANCER: UPDATED OVERALL SURVIVAL OUTCOMES FROM PHASE III PRODIGY.
Ottobre 28, 2024/da LuisaELACESTRANT (ORAL SELECTIVE ESTROGEN RECEPTOR DEGRADER) VERSUS STANDARD ENDOCRINE THERAPY FOR ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED BREAST CANCER: RESULTS FROM THE RANDOMIZED PHASE III EMERALD TRIAL.
Ottobre 21, 2024/da LuisaTRASTUZUMAB DERUXTECAN AFTER ENDOCRINE THERAPY IN METASTATIC BREAST CANCER.
Ottobre 14, 2024/da LuisaAICRO-MENTI A CONTATTO 8 NOVEMBRE 2024 ROMA-MILANO
Ottobre 10, 2024/da LuisaNEOADJUVANT NIVOLUMAB AND IPILIMUMAB IN RESECTABLE STAGE III MELANOMA.
Ottobre 7, 2024/da LuisaOVERALL SURVIVAL WITH PEMBROLIZUMAB IN EARLY-STAGE TRIPLE-NEGATIVE BREAST CANCER.
Ottobre 1, 2024/da Luisa8°GIORNATA NAZIONALE SIPO-CONVEGNO INTERREGIONALE SIPO VENETO-TRENTINO ALTO ADIGE 30 SETTEMBRE 2024, BOLZANO
Settembre 24, 2024/da LuisaCORTICOSTEROIDS FOR IMMUNE-RELATED ADVERSE EVENTS AND CHECKPOINT INHIBITOR EFFICACY: ANALYSIS OF SIX CLINICAL TRIALS.
Settembre 23, 2024/da Luisa
Scorrere verso l’alto
